Moderna, Inc.
Nasdaq: MRNA·Cambridge, Massachusetts·CIK 0001682852
- Price
- $215.27
- Base IV
- $3.87
Valuation snapshot
At $215.27, the price is above even our bull case of $21.79.
Values per share, from an .
- No growth
- …
- Loading earnings power
- Base case
- $3.87
- 2% of the price · range -$3.37–$21.79
- Price vs base case
- 5466% above
- $215.27 against $3.87
- Base case · our researched forecast, 2026-11-15See the research ↗
- Price vs base · derived: price − base caseWhat the price expects ↗
- Price · StockValuer price feed, 2026-11-16 closeno link today
The price has fallen 3.6% since this valuation was struck on 2026-11-15, so some of the gap opened up after these figures were set.
Whisker on the base case runs bear -$3.37 to bull $21.79, cut off at zero. Values per share.
Price against each value
- Bear case
- -$3.37
- —
- No growth
- …
- —
- Base case
- $3.87
- Price 5,466% above
What does Moderna do?
Moderna develops and manufactures mRNA-based vaccines and therapeutics to treat and prevent infectious diseases, cancers, and rare genetic disorders.
It brought in $2.5B of sales in the 12 months to Sep 2026.
Led by Stéphane Bancel, Chief Executive Officer since 2011. Meet the Moderna Team
- Industry
- Healthcare
- Based in
- Cambridge, Massachusetts
- Trades on
- Nasdaq as MRNA
Here is where each dollar a customer pays ends up. For every $1 of sales in the 12 months to Sep 2026, it spent about $2.10, so it lost $1.10 on each dollar. The biggest cost is research and development, $1.05 of every dollar.
- Making what it sells72¢
- Research and development$1.05
- Admin costs39¢
- Tax2¢
- Interest and other income came back in+8¢
- Lost on each dollar−$1.10
Who pays Moderna, and for what?
Moderna makes vaccines using mRNA technology. In 2025, it sold COVID vaccines Spikevax and mNEXSPIKE and the RSV vaccine mRESVIA. It also earned money from manufacturing agreements, grants, research partnerships, and licensing.
It sells vaccines mainly to wholesalers and distributors in the U.S., and also to retailers, healthcare providers, foreign governments, and international organizations.
COVID vaccines
93%Combined sales of Spikevax and mNEXSPIKE; the report does not split sales between them.
mNEXSPIKE prefilled syringe cartonImage: U.S. National Library of Medicine RSV vaccine
0%Sales of mRESVIA.
Manufacturing readiness
4%Payments under government agreements to keep manufacturing capacity ready.
Moderna’s UK Drug Substance Manufacturing FacilityImage: Moderna Grants
1%Funding from government and private organizations for research.
Research collaborations
1%Revenue from partnerships to develop potential medicines.
Licensing and royalties
1%Revenue from licensing COVID vaccine intellectual property in Japan.
Where its work physically happens, beyond headquarters:
- Moderna Technology Center — Norwood, United States. The campus supplies clinical programs and commercial vaccine drug substance, with an expansion underway to add U.S. drug product manufacturing and packaging.
- Marlborough biomanufacturing facility — Marlborough, United States. This purpose-built facility began supplying clinical batches for intismeran autogene and supports its potential commercial launch.
- Moderna Innovation and Technology Centre — Harwell, United Kingdom. The facility is designed to supply mRNA respiratory vaccines for UK seasonal programs, with capacity for up to 100 million doses annually and approximately 250 million during a pandemic.
- Laval mRNA manufacturing facility — Laval, Canada. The facility produces Spikevax drug substance for Canadian supply, is approved as a drug substance site for mRESVIA, and has capacity for up to 100 million doses annually.
- Moderna Technology Centre Melbourne — Clayton, Australia. This licensed facility supports end-to-end mRNA vaccine manufacturing in Australia, with capacity for up to 100 million doses annually.
How is the business doing?
Sales grew from $803M in 2020 to $1.9B in 2025, about 19% a year.
It still spends more to run the business than it brings in: an operating loss of $1.16 per sales dollar, wider than 95¢ in 2020.
It used $2B more cash than it generated in the 12 months to Sep 2026, paid for out of savings or new money.
What does management say it's aiming for?
Moderna says its purpose is to help as many people as possible with mRNA medicines.
“Our mission is to deliver the greatest possible impact to people through mRNA medicines.”
Who is responsible for the plan?
- Stéphane BancelChief Executive Officer
He leads Moderna as its chief executive officer. Moderna earns most of its revenue from vaccine sales.
- Ester BanqueChief Commercial Officer
She leads Moderna’s commercial organization. That organization supports sales of Moderna’s respiratory vaccines.
- Rose LoughlinExecutive Vice President, Research
She leads Moderna’s platform science and therapeutics research organization. That research supports Moderna’s mRNA platform for vaccines and investigational therapeutics.
Roles checked November 7, 2026.
What management says it is working on now:
Grow vaccine sales
Moderna aims to expand geographically and launch new products. It expects its government partnerships in the UK, Canada, and Australia and U.S. uptake of mNEXSPIKE to support growth.
Moderna 2025 Form 10-K, Item 1Reduce costs
Management plans further cost reductions in 2026 and 2027, including changes to manufacturing and greater use of digital tools.
Moderna 2025 Form 10-K, Item 1Advance selected medicines
Moderna is concentrating development work on vaccines and treatments for infectious diseases, cancer, and rare diseases.
Moderna 2025 Form 10-K, Item 1Develop its mRNA technology
Management continues to work on early cancer and vaccine programs and on the technology used to design, deliver, and make mRNA medicines.
Moderna 2025 Form 10-K, Item 1
- Research and development spending, 2026
- Approximately $2.9 billion
- Moderna second-quarter 2026 earnings release
- Selling and administrative spending, 2026
- Approximately $1.0 billion
- Moderna second-quarter 2026 earnings release
- Cash and investments, Year-end 2026
- $4.7 billion to $5.2 billion
- Moderna second-quarter 2026 earnings release
What's changing right now?
Growth is slowing. In Q3 2026 it sold 29% more than a year earlier. The year before, quarters averaged 47%.
Its operating margin is wider than a year ago: 10¢ per sales dollar, against a loss of 26¢.
Since Oct 2026 the share price has fallen 3%, from $222.76 to $215.27.
Recently
November 6, 2026
Third-quarter revenue (peak vaccine-season quarter) changed to $1.3B
Moderna Q3 2026 results (8-K Ex. 99.1)September 30, 2026
Research spending, third quarter changed to $583.0M
Moderna Q3 2026 Form 10-QDecember 31, 2025
COVID vaccine sales, full year changed to $1.8B
Moderna 2025 Form 10-K
Coming up
November 6, 2026
Third-quarter results
Moderna is scheduled to report and discuss third-quarter results, providing an update on vaccine sales and spending.
Moderna Events & PresentationsTiming not specified
Cancer treatment filing plans
After announcing positive late-stage melanoma trial results, Moderna and Merck said they would discuss approval submissions for intismeran with regulators.
Merck and Moderna announce intismeran Phase 3 resultsEnd of 2026
European COVID vaccine contract expiry
Moderna says a competitor’s European Commission contract has excluded its COVID vaccines from many European markets. The contract is due to expire at year-end.
Moderna 2025 Form 10-K, Item 1A
Our own estimate moved too: the base case went from $10.86 to $3.87 a share between our last two valuations. The biggest reason: Third-quarter revenue (peak vaccine-season quarter) moved from an unreported prior value to $1.3B, as reported in Moderna Q3 2026 results (8-K Ex. 99.1).
What could go wrong?
No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.
Uncertain vaccine demand
COVID vaccination rates could fall further, while changing eligibility recommendations could limit demand for COVID and RSV vaccines. Lower COVID vaccine sales drove much of Moderna’s 2025 revenue decline.
From the company's own filingsWould hit how fast sales growModerna 2025 Form 10-K, Items 1A and 7
Strong competitors
Larger vaccine makers compete with Moderna on contracts, price, and distribution. Moderna says competitor agreements have kept its COVID vaccines out of many European markets.
From the company's own filingsWould hit how fast sales growModerna 2025 Form 10-K, Item 1A
New medicines may be delayed
Regulators can require more evidence, limit who may receive a vaccine, or decline approval. These decisions could delay launches and add costs.
From the company's own filingsWould hit how fast sales growModerna 2025 Form 10-K, Item 1A
Clinical trials may fail
Promising early results may not hold up in larger studies. A failed or delayed trial could prevent a new vaccine or treatment from reaching patients.
From the company's own filingsWould hit how fast sales growModerna 2025 Form 10-K, Item 1A
High spending relative to sales
Moderna reported $1.94 billion of 2025 revenue and $5.02 billion of operating expenses. If sales growth or cost reductions fall short, its losses could remain substantial.
From the company's own filingsWould hit how much of each sale it keepsModerna 2025 Form 10-K, Item 7
Shared technology risks
A problem with an mRNA ingredient, delivery method, or manufacturing process could affect more than one medicine in development.
From the company's own filingsWould hit how much it has to reinvestModerna 2025 Form 10-K, Item 1A
Guidance implies Q4 2026 revenue below Q4 2025's $678M, so the trailing base includes a strong quarter that may not repeat.
From our researchWould hit how fast sales growModerna Q3 2026 results (8-K Ex. 99.1)
Excluding the $950M settlement payment, the business reportedly burned about $609M of operating cash in Q3 2026 despite reporting a profit.
From our researchWould hit how much of each sale it keepsModerna Q3 2026 earnings coverage
Is it a good business?
From 2018 to 2025 it earned between -963% and 148% on the capital invested in it, a median of -40%. Its cost of capital in the latest valuation is 10.2%; returns were above it in 2 of the 8 years.
From 2018 to 2025 it earned between -44% and 86% on its shareholders' equity, a median of -31%.
Over 8 years its operating margin ranged from $9.06 to 72¢ per sales dollar, a median of $1.08. Gross margin ran from 31¢ to 99¢.
Cost of capital 10.2%
The number of shares grew 10% in a year, so each share owns a smaller slice of the business.
It owes $1.8B more than it holds in cash. The latest four quarters had no positive operating profit to compare with that debt.
What might it be worth?
The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .
Today a share costs $215.27. Our put its value between -$3.37 and $21.79, with $3.87 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .
Bear case, -$3.37
This scenario assumes Moderna's sales, which have shrunk from about $19 billion in 2022 to about $2.5 billion over the last year, keep drifting lower as fewer people get COVID shots, and that the company only barely stops losing money.
Base case, $3.87
This scenario assumes Moderna's sales dip slightly next year from about $2.5 billion and then grow steadily as new vaccines add to its COVID shots, while cost cuts make the company modestly profitable.
Bull case, $21.79
This scenario assumes Moderna's recent pickup, with sales up 29% in its latest quarter and its first profit in years, turns into a lasting recovery as several new vaccines succeed and its large factories run much fuller.
Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.
Why the gap?
The price is far above anything our model can explain.
We value Moderna at $3.87 a share, assuming sales grow 5.7% a year. Even if sales doubled every year for the next 5 years, our model would still value it below today's $215.27. Over the last 5 years, sales shrank 26.6% a year.
Keep in mind: investors are likely paying for things this model leaves out, such as new businesses or many more years of fast growth.
What would make Moderna worth $215.27 to you?
Try your own numbersWe're not very sure of this range: it scores 22 out of 100 on our checks. The weakest point is scenario dispersion.
Test the assumptions
Our base value of $3.87 rests on three assumptions. Change any of them to see how the value per share responds.
- Revenue growth, 5-year average5.7%
Next year -5.3%, then about 9%
- Operating margin15.0%
- Long-term growth rate2.5%
This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.
Base estimate
$3.87 -98.2%

